Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

NCT01514448 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma (mRCC)

Interventions

DRUG: Everolimus (RAD001)

Sponsor

Novartis Pharmaceuticals